GlassScriptPhysician profile
Christopher J Christensen
NPI 1295787802
$4,965.26
in general payments reported to CMS, 2019-2025
38 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $948 · 2021: $606 · 2022: $772 · 2023: $541 · 2024: $588 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,141.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,224.52 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Intercept Pharmaceuticals, INC. | $543.06 | 2019-2020 | |
| Celgene Corporation | $529.92 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $443.95 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $351.97 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $246.18 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.47 | 2020-2024 | Xifaxan, Trulance |
| Mirum Pharmaceuticals, INC. | $220.39 | 2025 | Livmarli |
| Gilead Sciences, INC. | $157.43 | 2019-2025 | |
| Ardelyx, INC. | $135.07 | 2023-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $124.75 | 2022 | |
| Madrigal Pharmaceuticals | $96.63 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $82.45 | 2019-2022 | |
| Allergan, INC. | $56.97 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $54.35 | 2022-2023 | Terlivaz |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $45.75 | 2021-2023 | Monoferric |
| Cumberland Pharmaceuticals, INC. | $42.18 | 2020-2021 | |
| Redhill Biopharma INC. | $34.06 | 2021-2022 | |
| Braintree Laboratories, INC. | $31.07 | 2020-2024 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $27.22 | 2022-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $26.91 | 2024-2025 | Voquezna |
| Ucb, INC. | $25.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.65 | 2024 | Dupixent |
| Genzyme Corporation | $23.17 | 2025 | |
| Celltrion USA INC. | $21.28 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $20.58 | 2020 | |
| Olympus America INC. | $19.83 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.56 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $18.97 | 2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $18.75 | 2024 | |
| Qol Medical, LLC | $13.72 | 2023 | Sucraid |
| Fujifilm Healthcare Americas Corporation | $13.57 | 2024 | Utaswako Afp-L3 |
| Lilly USA, LLC | $13.48 | 2025 | Omvoh |
| Boston Scientific Corporation | $12.42 | 2022 | |
| Romark Laboratories, Lc | $11.42 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.